Welcome to Elekta's Press Room! If you're a member of a treatment center's communications team, a journalist, reporter, producer or writing for a publication or broadcast and have an inquiry, contact us at For investor-related information, click here.

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 120 countries and listed on Nasdaq Stockholm. For more information, visit or follow @Elekta on Twitter.

Featured stories

Linac-based cranial SRS a mainstay in many departments

While Leksell Gamma Knife® stereotactic radiosurgery (SRS) is the undisputed gold standard for treating cranial indications, the linear accelerator maintains its position as the most widely used platform for cranial SRS – and its capabilities have only improved in recent years with advances in beam-shaping and beam delivery speed. In a recent Elekta webinar titled…

Elekta maintains its unrelenting focus on innovation to help cancer patients worldwide

On behalf of Elekta, I would like to welcome everyone to ESTRO 2022 in Copenhagen! This is my first ESTRO as Executive Vice President of Europe. Previously, I worked for Philips, where we developed imaging technologies vital in diagnosing diseases and disorders throughout the body –  cancer being one of those. Now, I am honored…

Improving daily treatment with proton arc therapy

Proton arc therapy is an advanced radiation therapy technique that consists of a continuous delivery of a proton beam as the gantry rotates around the patient. During this rotation, the beam energy and intensity are adjusted to confer higher conformality to the tumor, more efficient delivery and increased plan robustness. Preliminary results for Spot-scanning proton…

More stories

Recent press

Communications contacts

Mattias Thorsson
Head of Corporate Communications and Public Affairs

Tel: +46 70 865 8012
Time zone: CET – Central European Time

Raven Canzeri
Global Director, Media Relations

Tel: +1 770 670 2524
Time zone: ET – Eastern Time

Kris Walmsley
Corporate Communications Manager

Tel: +46 8 587 25471
Time zone: CET – Central European Time